Open AccessPHARMACOECONOMIC APPROACHES FOR PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS
Author(s) -
Ihor Hayduchok,
Вікторія Шаповалова,
Константин Евгеньевич Ищейкин,
Valentyna Chopyak,
В. В. Шаповалов,
В. В. Шаповалов
Publication year - 2021
Publication title -
lìkarsʹka sprava/lìkarsʹka sprava
Language(s) - English
Resource type - Journals
eISSN - 2706-8803
pISSN - 1019-5297
DOI - 10.31640/jvd.1-2.2021(11
Subject(s) - medicine , pharmacotherapy , azathioprine , rheumatoid arthritis , pharmacoeconomics , pharmacy , biosimilar , pharmacovigilance , tofacitinib , pharmacology , intensive care medicine , drug , family medicine , disease
. With the spread of the coronavirus pandemic, the role of pharmacotherapy of rheumatoid arthritis (RA) among patients with dual health disorders and in patients with systemic diseases is growing. This article is devoted to pharmacoeconomic for the pharmacotherapy of RA based on ABC/VEN analysis. Materials and methods. International and national medical and technological documents on standardization of medical care of RA, as well as scientific sources were used for regulatory, documentary and pharmacoeconomic analysis. ABC analysis was performed as a tool to study the cost of purchasing drugs. VEN analysis was performed to classify drugs into categories V, E and N on the principles of evidence-based medicine, forensic pharmacy, evidence-based pharmacy. Results. On the first stage of the research was conducted clinical and pharmacological analysis, the next stages - marketing and pharmacoeconomic analysis. Based on the ABC/VEN analysis, a matrix of the consolidated ABC/VEN analysis was developed. Discussion. The largest share (66.7 %) falls on the ATC classification code L "Antineoplastic and immunomodulatory agents". According to the results of marketing analysis tablets occupy 50 % of doctors' appointments; 75 % of the studied drugs have an unlimited validity of registration certificates. Ranking of country of origin of manufacturers of studied drugs: Germany – 37.6 %. Category A included five drugs’ INN (Mycophenolic acid, Azathioprine, Cyclophosphamide, Methotrexate, Ciclosporine), the cost of one dose is 5241.1 UAH, which is 78.12 % of the total cost of treatment for a patient with RA. It was found that six drugs INN (Methotrexate, Sulfasalazine, Hydroxychloroquine, Azathioprine, Ciclosporine, Cyclophosphamide) belong to category V (Vital). Conclusion. The introduction of information about pharmacoeconomic for pharmacotherapy of RA in the activities of health care institutions will ensure proper organization of the order of drug circulation at the stages of prescribing, prescribing, storage, accounting, quality control, transportation, release, destruction, licensing in accordance with current medical and pharmaceutical legislation.